Hepatitis B Virus Reactivation Potential Risk Factors in Hepatocellular Carcinoma via Transcatheter Arterial Chemoembolization: A Retrospective Research
Table 2
Characteristics and changes in patients with HBV reactivation and those without HBV reactivation.
Characteristics
HBV reactivation (n = 42)
No reactivation (n = 66)
t or χ2
value
Gender
0.230
0.632
Male
28
41
Female
14
25
Age (years)
57.40 ± 9.59
59.51 ± 10.6
−1.046
0.298
Child-Pugh grade
2.256
0.133
A
24
47
B
18
19
HBeAg
2.494
0.114
Positive
25
29
Negative
17
37
Liver cirrhosis
2.693
0.101
Yes
20
42
No
22
24
HBV DNA before TACE (copies/mL)
17.852
<0.001
≥104
25
13
<104
17
53
Number of nodules
1.299
0.255
Single
29
52
Multiple
13
14
Tumor diameter (cm)
6.83 ± 2.12
6.65 ± 2.07
0.441
0.660
PVTT
0.003
0.959
Yes
10
16
No
32
50
AFP before TACE (ng/mL)
463.78 ± 251.57
430.44 ± 254.21
0.667
0.506
AFP after TACE (ng/mL)
333.90 ± 200.31
244.89 ± 174.47
2.435
0.017
T cells before TACE
CD3+ (%)
55.77 ± 9.72
55.10 ± 8.17
0.387
0.700
CD4+ (%)
26.82 ± 4.63
26.76 ± 4.12
0.068
0.946
CD4+/CD8+
0.94 ± 0.11
0.96 ± 0.14
–0.905
0.367
T cells after TACE
CD3+ (%)
48.57 ± 6.28
51.97 ± 5.40
−2.992
0.003
CD4+ (%)
20.91 ± 3.33
23.95 ± 3.30
−4.638
<0.001
CD4+/CD8+
0.72 ± 0.11
0.86 ± 0.13
−2.393
0.018
AFP, alpha-fetoprotein; PVTT, portal vein tumor thrombus; TACE, transcatheter arterial chemoembolization; HBeAg, hepatitis B e antigen.